The MspA nanopore platform demonstrated using the intrinsically disordered transactivation domain of tumor suppressor p53 (p53-TAD) showed that MspA can stably capture p53-TAD and resolve up to six distinct current states with frequent interconversions, revealing a rich conformational landscape.
Abstract
Investigating the conformational dynamics of intrinsically disordered proteins (IDPs) is essential to understanding how their structural heterogeneity underlies function and how their dysregulation contributes to diseases. Here, we utilized an MspA nanopore-based approach for studying the conformational dynamics and interactions of IDPs at the single-molecule level. The platform was demonstrated using the intrinsically disordered transactivation domain of tumor suppressor p53 (p53-TAD), one of the important proteins in cancer biology. We showed that MspA can stably capture p53-TAD and resolve up to six distinct current states with frequent interconversions, revealing a rich conformational landscape. The nanopore also detected the effect of a cancer-associated double mutational variant, N29K/N30D. Combining experiments with steered molecular dynamics simulations, we showed that the mutant sampled compact conformational states more frequently than wild type, consistent with previous NMR studies. Importantly, the MspA platform enabled direct monitoring of E3 ligase MDM2 binding to p53-TAD and resolved how this interaction is inhibited by anti-cancer compound epigallocatechin gallate (EGCG). Notably, EGCG stabilizes one of the six states sampled by p53-TAD, providing a mechanistic explanation for its inhibitory effect. Together, these findings demonstrate the promise of the nanopore platform for label-free monitoring of IDP conformational dynamics, modulation, binding and inhibition at single-molecule resolution.
This study demonstrates that PKM2 mutations dynamically remodel the binding pocket and allosteric communication to facilitate shikonin recognition, highlighting the newly identified pocket as a promising therapeutic site for future PKM2 targeted drug design.
MicroRNA (miRNA)-guided gene silencing depends on the accurate assembly and regulation of the RNA-induced silencing complex (RISC), in which Argonaute-2 (Ago2) interacts with accessory proteins to facilitate complex stability and catalytic activity. Staphylococcal nuclease domain-containing protein 1 (SND1) is an impor...
Jittasak Khowsathit, Yuvaraj Ravikumar, Manu Deeudom et al.· International Journal of Mol...· 0 citations
Complementary strategies, including covalent stabilization and targeted degradation, further extend this framework, establishing mutation-encoded structural vulnerabilities as actionable therapeutic opportunities, in which oncogenic missense mutations can generate druggable neo-pockets.
Lin-Wan Song, Hua Wang· Medical Review· 0 citations
An extensive molecular dynamics simulations study to investigate the conformational dynamics and unfolding pathway of the TAF15-RRM domain in 8 M urea revealed that unfolding proceeds through stable, denaturant/temperature-accelerated partially unfolded intermediate ensembles that, by analogy with aggregation-prone int...
Vishakha Chaudhary, Priyanka Kataria, Kusum Yadav et al.· Journal of Biomolecular Stru...· 0 citations
Breast cancer is one of the most common cancers worldwide. Approximately 30%–40% of breast cancers harbor mutations in the TP53 gene, leading to structural and functional alterations in the p53 protein. These changes result in mutant proteins that are unable to perform their canonical tumor suppressor functions and, in...
Ricardo J. F. Ferreira, L. Gonçalves, Mattia Mori et al.· ChemMedChem· 0 citations
A proteoform-by-environment model for IDP structure is established, in which phosphorylation effects are not fixed but are rewritten by the surrounding chemical environment, which distinguishes broad contact accessibility from the residue-level contacts that dominate each condition.
Ashlyn N. Dollar, Daniel W. Kelley, Ian K. Webb· Journal of the American Chem...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.